Literature DB >> 10501838

Absence of MHC class II gene expression in a patient with a single amino acid substitution in the class II transactivator protein CIITA.

V Quan1, M Towey, S Sacks, A P Kelly.   

Abstract

We investigated the underlying genetic defect in an immunodeficient patient who presented with recurrent bacterial infections in his late twenties and demonstrated a transcriptional defect in major histocompatibility complex (MHC) class II regulation. Transient heterokaryon analysis implicated functional loss of CIITA, the MHC class II transactivator protein, and in support of this MHC class II antigen expression was restored by stable transfection with the wild-type molecule. A single amino acid substitution, phenylalanine to serine, in the COOH-terminal portion of the CIITA sequence correlated with reduced transcription of both classical (HLA-DP, -DQ, and -DR) and nonclassical (HLA-DM and -DO) class II genes. The long survival of the patient, although remarkable, was not associated with partial CIITA function as evidenced by residual MHC class II expression. These data define at high resolution a region of CIITA that is essential for function in both professional and nonprofessional antigen presenting cells and which could potentially constitute a target for therapeutic intervention by novel factors with a propensity to downregulate MHC class II antigen expression.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10501838     DOI: 10.1007/s002510050579

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  9 in total

1.  Two distinct domains within CIITA mediate self-association: involvement of the GTP-binding and leucine-rich repeat domains.

Authors:  M W Linhoff; J A Harton; D E Cressman; B K Martin; J P Ting
Journal:  Mol Cell Biol       Date:  2001-05       Impact factor: 4.272

Review 2.  Class II transactivator: mastering the art of major histocompatibility complex expression.

Authors:  J A Harton; J P Ting
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

3.  Promoter-specific functions of CIITA and the MHC class II enhanceosome in transcriptional activation.

Authors:  Krzysztof Masternak; Walter Reith
Journal:  EMBO J       Date:  2002-03-15       Impact factor: 11.598

Review 4.  NLR proteins: integral members of innate immunity and mediators of inflammatory diseases.

Authors:  Jeanette M Wilmanski; Tanja Petnicki-Ocwieja; Koichi S Kobayashi
Journal:  J Leukoc Biol       Date:  2007-09-17       Impact factor: 4.962

5.  Relationship between polymorphism of class II transactivator gene promoters and chronic hepatitis B.

Authors:  Ying-Ren Zhao; Ling Gong; Ying-Li He; Fang Liu; Chang Lu
Journal:  World J Gastroenterol       Date:  2005-02-14       Impact factor: 5.742

6.  Splicing defect in RFXANK results in a moderate combined immunodeficiency and long-duration clinical course.

Authors:  Thomas Prod'homme; Benjamin Dekel; Giovanna Barbieri; Barbara Lisowska-Grospierre; Rina Katz; Dominique Charron; Catherine Alcaide-Loridan; Shimon Pollack
Journal:  Immunogenetics       Date:  2003-10-22       Impact factor: 2.846

7.  Progressive Ataxia and Neurologic Regression in RFXANK-Associated Bare Lymphocyte Syndrome.

Authors:  Essa Alharby; Mona Obaid; Mohammed A O Elamin; Makki Almuntashri; Ismail Bakhsh; Manar Samman; Roy W A Peake; Ali Alasmari; Naif A M Almontashiri
Journal:  Neurol Genet       Date:  2021-04-09

Review 8.  Monogenic Adult-Onset Inborn Errors of Immunity.

Authors:  Frederik Staels; Tom Collignon; Albrecht Betrains; Margaux Gerbaux; Mathijs Willemsen; Stephanie Humblet-Baron; Adrian Liston; Steven Vanderschueren; Rik Schrijvers
Journal:  Front Immunol       Date:  2021-11-17       Impact factor: 7.561

9.  Recognition of HIV-1 peptides by host CTL is related to HIV-1 similarity to human proteins.

Authors:  Morgane Rolland; David C Nickle; Wenjie Deng; Nicole Frahm; Christian Brander; Gerald H Learn; David Heckerman; Nebosja Jojic; Vladimir Jojic; Bruce D Walker; James I Mullins
Journal:  PLoS One       Date:  2007-09-05       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.